Abstract | BACKGROUND: MATERIALS AND METHODS: hNIS cDNA expression vector was transfected into wild-type anaplastic thyroid cancer cells (ARO-W) which do not concentrate iodide. Stable trasfected cells were isolated (ARO-S) and analyzed by RT-PCR, radioiodide uptake and immunocyto-chemistry staining. 131I imaging and treatment were performed on mice bearing ARO-W and ARO-S xenograft tumors and tumor volume was recorded. RESULTS: The ARO-S cells showed clear hNIS expression on the cell membrane and accumulated 87-fold and 4.4-fold radioiodide of that of wild-type cells in vitro and in vivo, respectively. Radioiodide uptake was dependent on cell number and reached a maximum level at 20 minutes in vitro. The half life of radioiodide efflux was 12 minutes and 12 hours in vitro and in vivo, respectively. Administration of a therapeutic dose of 131I into mice bearing ARO-S tumors effectively inhibited tumor growth as compared to control mice. CONCLUSION:
|
Authors | Ya-Ju Hsieh, Chien-Chih Ke, Ren-Shyan Liu, Fu-Hui Wang, Kam-Tsun Tang, Chin-Wen Chi, Fu-Du Chen, Chen-Hsen Lee |
Journal | Anticancer research
(Anticancer Res)
2007 Jul-Aug
Vol. 27
Issue 4B
Pg. 2515-22
ISSN: 0250-7005 [Print] Greece |
PMID | 17695547
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Iodine Radioisotopes
- Radiopharmaceuticals
- Symporters
- sodium-iodide symporter
|
Topics |
- Animals
- Cell Line, Tumor
- Disease Models, Animal
- Gene Expression
- Genetic Therapy
- Humans
- Immunohistochemistry
- Iodine Radioisotopes
(pharmacokinetics, therapeutic use)
- Mice
- Neoplasm Transplantation
- Radionuclide Imaging
- Radiopharmaceuticals
(pharmacokinetics, therapeutic use)
- Reverse Transcriptase Polymerase Chain Reaction
- Symporters
(biosynthesis, genetics)
- Thyroid Neoplasms
(diagnostic imaging, genetics, metabolism, therapy)
- Transplantation, Heterologous
|